New Delhi, Mar 14 (PTI) Drug firm Eli Lilly on Tuesday said it has forayed into the dermatological space in the country with the launch of a product to treat moderate-to-severe plaque psoriasis.

The company has launched Copellor in the market after getting approval from the Drug Controller General of India (DCGI).

Also Read | West Bengal Weather Forecast: Rainfall, Thunderstorms Likely From March 14, Says Met Department.

The drug is designed to specifically target a protein that plays a role in triggering and maintaining inflammation in psoriasis.

"Our foray into the dermatology segment strengthens Lilly's promise of bringing innovative medicines to India. Global Studies show that the impact psoriasis has on a patient's quality of life is comparable to that of 'serious' diseases such as cancer and heart failure," Eli Lilly and Company - India & India Subcontinent Managing Director Vineet Gupta said in a statement.

Also Read | Reliance Health Infinity Policy Offers India's First Credit Score-Based Discount on Premium.

The availability of a new treatment like Copellor (Ixekizumab) will now empower healthcare providers with another option to successfully treat adults with moderate-to-severe plaque psoriasis and adult patients with active psoriatic arthritis, a huge unmet need in the country, he added.

Copellor is a prescription medicine to be used only on the advice of a dermatologist or rheumatologist and under medical supervision, the drug firm stated. Psoriasis is a chronic auto-immune disorder of the skin in which prolonged inflammation leads to dry, thick, raised, red patches on the skin that continuously shed silvery scales.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)